Biswasjit Das

7PUBLICATIONS
96CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursNanomaterials
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 24, 2026
A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.

|Aug 07, 2026
Associations of Age With Tumor Genomic Characteristics in Relapsed/Refractory Cancers Interrogated With the NCI-MATCH Trial Targeted Gene Panel Assay.

|Jul 28, 2026
Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388).

|Oct 09, 2025
Phase II Study of Vismodegib in Patients With SMO- or PTCH1-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.

Anne S Tsao, Zihe Song, Alan L Ho

|Jul 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).

Matthew Ingham, Jacob B Allred, Li Chen

|Oct 28, 2021
An Anti-inflammatory Fe3 O4 -Porphyrin Nanohybrid Capable of Apoptosis through Upregulation of p21 Kinase Inhibitor Having Immunoprotective Properties under Anticancer PDT Conditions.

Devashish Sengupta, Subhojit Das, Debdulal Sharma

Pageof 2

Frequent Collaborators

3 joint publications

Larry V Rubinstein

2 joint publications

Naoko Takebe

2 joint publications

Lyndsay N Harris

2 joint publications

Stanley R Hamilton